secwatch.observer — SEC 8-K summary
======================================

Issuer:     Theravance Biopharma, Inc. (TBPH)
CIK:        0001583107
Form:       8-K
Filed at:   2024-01-16T23:59:59+00:00
Accession:  0001104659-24-003852
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Patent settlement with Orbicular allows generic YUPELRI launch on April 23, 2039
--------------------------------------------------------------------------------

- Settlement resolves Hatch-Waxman litigation with Orbicular over YUPELRI (revefenacin).
- Orbicular granted royalty-free license to market generic revefenacin on or after April 23, 2039.
- Litigation continues against four other ANDA filers: Cipla, Eugia, Lupin, and Mankind Pharma.
- Settlement subject to review by U.S. DOJ and FTC as required by law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924003852/0001104659-24-003852-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583107/000110465924003852/tm243112d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-003852

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer